British CRO wins contract for Covid-19 challenge virus; Dutch agency aims to slash Zolgensma prices in half
Efforts are underway to develop a new challenge virus for SARS-CoV-2, and a British CRO is making its case.
Open Orphan said Monday that its subsidiary hVIVO signed a contract with Imperial College London to manufacture such a challenge virus. The contract is worth £3 million and hVIVO will develop the virus based on new emerging Covid-19 variants of concern. The company hopes to then use the virus in future challenge studies.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters